2,379 results on '"Rosell, R"'
Search Results
2. Long term abundance patterns of potamodromous brown trout in a large lacustrine catchment in County Fermanagh
3. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
4. HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
5. Propiedades mecánicas y tribológicas del material antifricción Al-Ni-grafito obtenido mediante extrusión en caliente
6. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial
7. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
8. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
9. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
10. Long term abundance patterns of potamodromous brown trout in a large lacustrine catchment in County Fermanagh
11. Some observations on the behaviour of lake-dwelling brown trout in Lower Lough Erne
12. Interannual variation in survival of wild Atlantic salmon smolts through a dynamic estuarine habitat
13. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
14. P2.10-09 Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study
15. P2.10-10 Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer
16. MA04.09 The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
17. EP12.01-20 Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)
18. P06-23: Inhibition of DNA Repair in Non-small Cell Lung Cancer Cells: Innovative ERCC1-XPF Small Molecule Inhibitors to Enhance Cisplatin Cytotoxicity
19. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma
20. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
21. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
22. Cancer immunotherapy of patients with HIV infection
23. Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
24. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
25. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
26. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
27. Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
28. EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
29. P08-20 Cytotoxic effects of the SOD mimic MnTnHex-2-PyP5+ and its combination with cisplatin in non-small cell lung cancer cells
30. EP08.02-011 Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
31. EP16.03-003 Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)
32. EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
33. EP05.01-001 Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
34. EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
35. EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
36. EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
37. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
38. Targeting PD-1/PD-L1 in lung cancer: current perspectives
39. Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
40. Cross‐cultural adaptation and validation of the Spanish version of the Paediatric Throat Disorders Outcome Test (T‐14)
41. First report of the novel atypical porcine pestivirus in Spain and a retrospective study
42. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
43. Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients
44. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study
45. 233P Breast cancer organoids mimic disease heterogeneity, allow high-throughput drug screening and show correlation with clinical response
46. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
47. Classification of atypical EGFR mutations in non-small cell lung cancer
48. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
49. KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block
50. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.